Risk factors
Acurx Pharmaceuticals (ACXP) risk factors
Item 1A of every Acurx Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors56 risks4 new3 dropped5 reworded
Acurx faces Nasdaq delisting risks due to stockholders' equity and bid price deficiencies, though compliance was later regained.
Filed Mar 12, 2026 - FY2024 10-K risk factors55 risks
Clinical-stage biopharmaceutical company dependent heavily on the success of its lead product candidate, ibezapolstat, for the treatment of CDI.
Filed Mar 17, 2025